Active, Not Recruiting Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors NCT04079712 Conditions Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +20 more Locations University of Alabama at Birmingham Cancer Center — Birmingham, Alabama, United States Banner University Medical Center - Tucson — Tucson, Arizona, United States University of Arizona Cancer Center-North Campus — Tucson, Arizona, United States City of Hope Comprehensive Cancer Center — Duarte, California, United States View all 46 locations View more locations Show fewer locations Loading locations... View Trial Details
